Although spontaneous regression is described in a proportion of cases, shared molecular features with cutaneous squamous cell carcinoma (cSCC), most notably TP53 (≈30-50%) and RAS (≈20-30%) mutations, support malignant potential and the need for timely treatment [3,4]. This evidence concerns the gene TP53 and skin squamous cell carcinoma.